» Articles » PMID: 38942169

Disparities in Metabolic Dysfunction-associated Steatotic Liver Disease and Cardiometabolic Conditions in Low and Lower Middle-income Countries: a Systematic Analysis from the Global Burden of Disease Study 2019

Abstract

Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic conditions affect populations across economic strata. Nevertheless, there are limited epidemiological studies addressing these diseases in low (LICs) and lower-middle-income countries (lower MICs). Therefore, an analysis of the trend of MASLD and cardiometabolic conditions in these countries is necessary.

Methods: From 2000 to 2019, jointpoint regression analysis was employed to calculate the prevalence, mortality, and disability-adjusted life years (DALYs) for cardiometabolic conditions including MASLD, type 2 diabetes mellitus (T2DM), dyslipidemia (DLP), hypertension (HTN), obesity, peripheral artery disease (PAD), atrial fibrillation and flutter (AF/AFL), ischemic heart disease (IHD), stroke, and chronic kidney disease from HTN and T2DM, in LICs and lower MICs (according to the World Bank Classification 2019) using the Global Burden of Disease 2019 data.

Results: Among the eleven cardiometabolic conditions, MASLD (533.65 million), T2DM (162.96 million), and IHD (76.81 million) had the highest prevalence in LICs and Lower MICs in 2019. MASLD represented the largest proportion of global prevalence in these countries (43 %). From 2000 to 2019, mortality in LICs and lower MICs increased in all cardiometabolic conditions, with obesity-related mortality having the highest increase (+134 %). During this timeframe, there were increased age-standardized death rates (ASDR) from obesity, PAD, and AF/AFL. From all conditions, the DALYs-to-prevalence ratio was higher in LICs and lower MICs than the global average.

Conclusion: The burden of MASLD and cardiometabolic conditions is increasing worldwide, with LICs and lower MICs experiencing higher (DALYs) disability per prevalence. As these conditions are preventable, counteracting these trends requires not only the modification of ongoing actions but also the strategizing of immediate interventions.

Citing Articles

Regional insights into the relationship between metabolic associated steatotic liver disease and chronic kidney disease: a socioeconomic perspective on disease correlation.

Bai J, Zhang L, Zhang M, Hao Y, Yi Z, Zhou Y BMC Public Health. 2025; 25(1):993.

PMID: 40082841 PMC: 11907813. DOI: 10.1186/s12889-025-22188-3.


Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021.

Feng G, Targher G, Byrne C, Yilmaz Y, Wong V, Lesmana C JHEP Rep. 2025; 7(3):101271.

PMID: 39980749 PMC: 11840544. DOI: 10.1016/j.jhepr.2024.101271.


The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021.

Tham E, Tan D, Danpanichkul P, Ng C, Syn N, Koh B Liver Int. 2025; 45(3):e70001.

PMID: 39927433 PMC: 11808647. DOI: 10.1111/liv.70001.


MAP17 is a Novel NASH Progression Biomarker Associated with Macrophage Infiltration, Immunotherapy Response, and Oxidative Stress.

Huang Z, Chen J, Liu S, Xiang X, Long Y, Tan P J Inflamm Res. 2025; 18():601-619.

PMID: 39839187 PMC: 11747966. DOI: 10.2147/JIR.S497737.


The global, regional, and national patterns of change in the burden of bacterial pyoderma from 1990 to 2019 and the forecast for the next decade.

Wang H, Bai Z, Shen C, Kou J, Zhu Y, Xie H Sci Rep. 2025; 15(1):1810.

PMID: 39805883 PMC: 11730338. DOI: 10.1038/s41598-025-85995-z.